Prevalence of lower limb deep venous thrombosis among adult HIV positive patients attending an outpatient clinic at Mulago Hospital by Vululi, Sosthene T et al.
Vululi et al. AIDS Res Ther  (2018) 15:3 
https://doi.org/10.1186/s12981-018-0191-1
RESEARCH
Prevalence of lower limb deep venous 
thrombosis among adult HIV positive patients 
attending an outpatient clinic at Mulago 
Hospital
Sosthene Tsongo Vululi1*, Samuel Bugeza2, Muyinda Zeridah3, Henry Ddungu4, Akello Betty Openy5, 
Mubiru Frank6 and Rosalind Parkes‑Ratanshi7
Abstract 
Background: Deep venous thrombosis (DVT) and its major complication pulmonary embolism (PE) are collectively 
known as venous thromboembolism. In Uganda, the prevalence of DVT among HIV patients has not been previ‑
ously published. The aim of the study was to determine the prevalence and sonographic features of lower limb deep 
venous thrombosis among HIV positive patients on anti‑retroviral treatment (ART).
Methods: This was a cross sectional study in which HIV positive patients on ART were recruited from an out‑patient 
HIV clinic at Mulago National Referral Hospital. Patients were randomly selected and enrolled until a sample size of 
384 was reached. Study participants underwent compression and Doppler ultrasound studies of both lower limb 
deep veins using Medison Sonoacer7 ultrasound machine.
Resuts: We found a prevalence of DVT of 9.1% (35 of 384 participants) among HIV patients on ART. The prevalence 
of latent (asymptomatic) DVT was 2.3%. Among 35 patients with DVT, 42.8% had chronic DVT; 31.1% had acute 
DVT and the rest had latent DVT. Among the risk factors, the odds of occurrence of DVT among patients with pro‑
longed immobility were 4.81 times as high as in those with no prolonged immobility (p = 0.023; OR = 4.81; 95% CI 
1.25–18.62). Treatment with second line anti‑retroviral therapy (ART) including protease inhibitors (PIs) was associated 
with higher odds of DVT occurrence compared with first line ART (p = 0.020; OR = 2.38; 95% CI 1.14–4.97). The odds 
of DVT occurrence in patients with a lower CD4 count (< 200 cells/µl) were 5.36 times as high as in patients with CD4 
counts above 500 cells/µl (p = 0.008). About 48.6% patients with DVT had a low risk according to Well’s score.
Conclusion: DVT was shown in nearly 10% of HIV patients attending an out‑patient clinic in an urban setting in 
Uganda. Risk factors included protease inhibitors in their ART regimen, prolonged immobility, and low CD4 count 
(< 200 cells/µl). Clinicians should have a low threshold for performing lower limb Doppler ultrasound scan examina‑
tion on infected HIV patients on ART who are symptomatic for DVT. Therefore, clinicians should consider anti‑coagu‑
lant prophylaxis and lower deep venous ultrasound screening of patients who are on second line ART regimen with 
low CD4 cell counts and/or with prolonged immobility or hormonal contraception.
Keywords: Lower limb veins anatomy, Well’s score, Doppler ultrasound, DVT echo pattern
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
AIDS Research and Therapy
*Correspondence:  sosthenetsongo@gmail.com 
1 Makerere University College of Health Sciences (MakCHS), Kampala, 
Uganda
Full list of author information is available at the end of the article
Page 2 of 7Vululi et al. AIDS Res Ther  (2018) 15:3 
Background
Deep venous thrombosis is one of the most prevalent 
medical conditions [1]. The risk of DVT in the general 
population of South Africa is 0.10% a year [2]. HIV infec-
tion has been recognised as a hypercoagulable condition 
since the late 1980s and the current and other stud-
ies indicate that the prevalence in HIV positive patients 
is significantly increased [3, 4] with a two to tenfold 
increased risk in HIV infected patients compared to the 
general population. A large number of worldwide studies 
reported the frequency of DVT in HIV-infected patients 
ranging from 0.19 to 8% [5]. There is some evidence to 
suggest that anti-retroviral therapy (ART) may increase 
the risk of DVT [6]. There is limited work on DVT in sub-
Saharan Africa, especially Uganda. A study done by Man-
geni et al. in 2003 at Mulago Hospital showed that out of 
86 patients clinically suspected to have lower limb DVT, 
38 (44.2%) were found to have DVT after sonography [7]. 
Doppler ultrasound of lower limb deep veins presents an 
echo-pattern of the thrombus usually found in DVT. The 
thrombus may be anechoic, hypoechoic, heterogeneous 
or hyper-echoic depending on the age of the clot. To our 
knowledge, there has been no study conducted in East-
ern Africa to determine the prevalence of DVT in HIV 
positive patients. The aim of this study was to determine 
the prevalence of DVT in HIV outpatients on ART in 
Uganda and to appreciate the association between clini-
cal presentation and sonographic features of DVT.
Materials/methods
This study was conducted from May 2014 to January 
2015. This was a cross sectional study in which adult HIV 
positive outpatients on ART were recruited from the 
Infectious Diseases Institute and HIV clinic at Mulago 
Hospital. Participants were attending for routine follow-
up of their HIV. Participants unable to understand the 
procedure and unable to consent for ultrasound scan 
examination were excluded. Using systematic sampling 
[8], patients who met the inclusion criteria were enrolled 
until the sample size of 384 was reached. Informed con-
sent was signed by each participant before ultrasound 
scan examination. Study participants underwent Doppler 
ultrasound studies of both lower limb deep veins using an 
ultrasound machine (Medison Sonoacer7).
The patients were categorized depending on the 
ultrasound findings: latent DVT when there was lack 
of venous compressibility or reduction of blood flow 
on ultrasound; acute DVT was diagnosed in the pres-
ence of hypoechoic thrombus with limited venous com-
pressibility; chronic DVT when there was hyper echoic 
or heterogeneous thrombus and limitation of venous 
compressibility. Proximal DVT was diagnosed in the 
presence of a thrombus in common femoral vein up to 
popliteal vein whereas distal DVT was seen below the 
popliteal fossa. A Wells score was calculated for each 
patient based on the presence of clinical symptoms. At 
the time of the study, WHO and Ugandan guidelines rec-
ommended first line ART to be backbone of nucleoside 
reverse transcriptase inhibitors (lamivudine/zidovudine 
or lamivudine/tenofovir) with either nevirapine or efa-
virenz non-nucleoside reverse transcriptase inhibitors. 
Second line regimens for those who had failed first line 
was either of these backbones with a protease inhibitor; 
either ritonavir boosted lopinavir or ritonavir boosted 
atazanavir. A structured non-disguised questionnaire was 
used and acquired data were entered using EPI—DATA 
3.02 and exported to be analysed using a statistical soft-
ware program STATA 13.
The study was approved by the IDI Scientific Review 
Committee (SRC) and the School of Medicine Research 
and Ethics Committee (SOMREC).
Results
Three hundred eighty-four patients were enrolled. 286 
participants were aged between 18 and 50 years (74.5%) 
and the remainder were above 50 years (25.5%). The most 
common occupation in 38.5% of participants was busi-
ness (see Table 1).
Out of 384 study participants, 229 (59.6%) were on first 
line ART regimen and 155 (40.4%) participants were on 
second line.
The prevalence of lower limb DVT was 9.1% (35/384) 
(Table  2). Among 35 participants found with DVT, 
26 (74.3%) were symptomatic and 9 (25.7%) partici-
pants asymptomatic for DVT. The prevalence of latent 
DVT among HIV patients on ART was 2.3%. Among 
Table 1 Study participants by gender, age-group catego-
ries and occupation
Demographics Number (n) Percentage (%)
Gender
 Male 126 32.8
 Female 258 67.2
Age (years)
 18–29 40 10.4
 30–39 110 28.7
 40–49 136 35.4
 ≥ 50 98 25.5
Occupation
 Business 148 38.5
 Driver 18 4.7
 Farmer 43 11.2
 House wife 28 7.3
 Work in office 30 7.8
 Others 117 30.5
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35 patients with DVT, 31.1% had acute DVT, 42.8% had 
chronic DVT, and the rest had latent DVT (Figs.  1, 2). 
Among the patients with DVT, 30 (80.7%) had proximal 
DVT and 5 had distal DVT. Bilateral deep venous throm-
bosis was noted in 3/35 (0.08%) participants.
Among participants who had DVT, 4 (11.4%) reported 
the use of hormonal contraception. Patients with hor-
monal contraception use had a high probability of DVT 
(p = 0.024).
On the Wells scoring out of 35 patients with DVT, 
17 (48.6%) patients had a low probability of DVT, 8 
(22.9%) patients had moderate probability of DVT and 
10 patients had high probability of DVT. Study findings 
showed that among 35 patients with DVT, 23 (65.7%) 
patients had leg swelling (p < 0.0001).
In the bivariate analysis, study findings showed that 
prolonged immobility, platelets count, latest CD4 count, 
and ART line regimen had an association with deep 
venous thrombosis (see Table 3).
In the multivariate analysis (Table 4), the odds of occur-
rence of DVT among patients with prolonged immobil-
ity are 4.81 times as high as in those with no prolonged 
immobility. Being on second line ART regimen, is associ-
ated with higher odds of DVT occurrence compared with 
being on ART first line (OR =  2.38; 95% CI 1.14–4.97). 
Patients with a lower CD4 count (cd4 < 200 cells/µL) had 
5.36 times the odds of DVT occurrence than those with 
higher CD4 count (cd4 > 500 cells/µL).
Discussion
We found the prevalence of DVT in ambulatory HIV 
positive patients on ART to be 9.1% at the National Refer-
ral Hospital, Kampala, Uganda. This prevalence is higher 
Table 2 Prevalence of DVT in the study population
DVT Type of DVT
n (%) n (%)
Present 35 (9.1) Symptomatic for DVT Acute 11 (31.4)
Chronic 15 (42.9)
Asymptomatic for DVT Latent 9 (25.7)
Absent 349 (90.9)
Fig. 1 Chronic DVT. Transverse sonogram of 63 years old male HIV positive patient on HAART shows echogenic thrombus (white arrow) in the right 
common femoral vein (CFV) causing partial compressibility of the vein
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than previously reported in several studies among HIV-
infected patients in Western and African countries rang-
ing from 0.19 to 8% per year [6, 9–11] The prevalence 
of DVT in HIV-infected patients is within limits from 
previous studies although a little higher than in the gen-
eral population in Uganda [12] (1/1000  person-years of 
observation). This is especially striking as these patients 
were attending for routine follow up for their HIV and 
were not admitted as in-patients or attending hospital 
because they were unwell. To our knowledge, this is the 
first study to determine the prevalence of DVT among 
HIV sero-positive out patients on ART in Eastern Africa.
In this study, 15 of 35 patients found with DVT had 
hyperechoic thrombus (42%). The other sonographic 
characteristic of DVT noted in this study were the same 
characteristics reported in other studies [13, 14].
Majority of participants found with DVT had clini-
cal symptoms of this pathology (Table  2) and only few 
patients had latent DVT (2.3%). Almost half of HIV 
patients with DVT (48.6%) had a lower Wells score for 
DVT (Table  3). This suggests that DVT in this popula-
tion is difficult to predict clinically therefore Well’s score 
need to be altered to account for HIV infection although 
other studies have shown that patients with high score 
are likely to develop DVT [5]. This study demonstrates 
that infected HIV patients on ART may be asymptomatic 
for DVT according Wells score findings however they 
may develop an asymptomatic DVT. Based on the results 
of Wells score in this study, a compression ultrasound 
screening in HIV positive patients on ART may be help-
ful for early diagnosis.
There was a significant association between PIs con-
taining second line ART and deep venous thrombosis 
in patients (p  =  0.02) which is in keeping with several 
other studies. HIV-infected patients on second line ART 
regimen (PIs) have higher risk for blood clot formation 
than those on first line treatment [5, 8, 15, 16]. Studies 
supporting this association reported high rate of DVT 
among HIV-infected patients after the introduction of 
protease inhibitors in ART regimen [4].
This study shows significant association between hor-
monal contraception use and DVT (p  =  0.024) as per 
well known evidence for increased risk of VTE associ-
ated with combined hormonal contraceptive use gener-
ally [22].
Eleven (2.9%) of 384 participants had history of immo-
bility in the last 3  months. Among 35 participants with 
DVT, 4 (11.4%) had history of immobility (p  =  0.005). 
Fig. 2 Acute DVT. Transverse sonogram of a 23 years old man on second line HAART who presented with acute DVT of CFV. Ultrasound scan shows 
lack of compressibility of the left CFV, presence of heterogeneous thrombus (black arrow) in the lumen and absence of spontaneous Doppler signal
Page 5 of 7Vululi et al. AIDS Res Ther  (2018) 15:3 
This is also in line with other studies suggesting that 
chronic immobility (>  30  days) is a high risk for deep 
venous thrombosis [17–19]. These study findings were 
similar to the case–control study in 2008 conducted by 
Leibson and colleagues in 2008 [20, 21]. HIV patients are 
susceptible to develop opportunistic infections responsi-
ble of hospitalization, and this will put them at increased 
risk for DVT [15, 21–23].
Our study showed that among 23 participants (6%) 
with low CD4 cell counts (<  200  cells/mm3), 5 partici-
pants (14.3%) had DVT. Therefore, correlation between 
low CD4 and DVT was significant even after correct-
ing for immobility which may be associated with higher 
rates of opportunistic infections in people with low CD4 
counts. Several studies reported the same findings [5–
24]. The association between low CD4 count and DVT 
may be related to progressive immunosuppression and 
increasing hypercoagulable state [25]. Having a low CD4 
count can be associated with having an uncontrolled high 
HIV viral load. HIV with a high viral load is associated 
with hypercoagulable state. Unfortunately, viral load was 
not done in all patients recruited in this study therefore it 
was not possible to analyse any association between DVT 
and viral load.
Whilst newer lower molecular weight anti-coagulation 
is expensive for low resource settings, traditional anti-
coagulation with warfarin is cheap, although logistically 
difficult. Research into the cost–benefit of use of newer 
anti-coagulation or point of care monitoring of warfarin 
in patients at highest risk of DVT in our setting should be 
considered. The blood tests such as D-dimer, tissue factor 
(TF) and analysis of other coagulation biomarkers should 
also be considered in relation to blood clot formation in 
this population with hypercoagulable state.
Conclusion and recommendations
The prevalence of DVT among ambulatory HIV posi-
tive patients on ART is 9.1%. Majority of participants 
with DVT were symptomatic. Prolonged immobility, low 
CD4 count (<  200  cells/µl) and ART second line (PIs) 
were associated with risk of DVT. It is advisable to per-
form lower limb Doppler ultrasound scan examination 
on infected HIV patients on ART who are symptomatic 
for DVT. However, half of patients with a DVT had a 
Table 3 Distribution of DVT by patient characteristics: bivariate analysis
Characteristic Total population n (%) n = 384 DVT present n = 35 (9.1%) DVT absent 349 (89.1%) Chi square p value
Gender 0.88 0.35
 Male 126 (32.8%) 9 (25.7%) 117 (33.5%)
 Female 258 (67.2%) 26 (74.3%) 232 (66.5%)
Age (years) 0.32 0.574
 < 50 286 (74.5) 26 (74.3) 260 (74.5) 0.001 0.98
 50 years and above 98 (25.5) 9 (25.7) 89 (25.5)
Duration on ART (mean of years) 4.5 (2.5–8.5) 5.5 (2.5–8.5) 4.5 (2.5–8.5) 0.80
ART line status 6.17 0.01
 First line 229 (59.6%) 14 (40.0% 215 (61.6%)
 Second line 155 (40.4%) 21 (60%) 134 (38.4%)
Latest CD4 cell counts 6.73 0.04
 Less than 200 23 (6.0%) 5 (14.3%) 18 (5.2%)
 200–500 194 (50.5%) 20 (57.1%) 174 (49.9%)
 Above 500 167 (43.5) 10 (28.6%) 157 (45.0%)
Occupation 2.78 0.73
 Business 148 (38.5%) 11 (31.4%) 137 (39.3%)
 Driver 18 (4.7%) 2 (5.7%) 16 (4.6%)
 Farmer 43 (11.2%) 5 (14.3%) 38 (10.9%)
 House wife 28 (7.3%) 3 (8.7%) 25 (7.2)
 Work in office 30 (7.8%) 1 (2.9%) 29 (8.3%)
 Others 117 (30.5% 13 (37.1%) 104 (29.8%)
Prolonged immobility 10.21 0.005
 Yes 11 (2.9%) 4 (11.4%) 7 (2.0%)
 No 373 (97.1%) 31 (88.6%) 342 (98.0%)
Platelets count 235 (185–301) 206 (178–287) 236 (186–303) 0.10
BMI (median (IQR) 23.5 (21.5–26.9) 24.6 (21.9–28.1) 23.4 (21.5–26.8) 0.37
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low Wells score suggesting that they did not have typical 
clinical features of DVT. Therefore, clinicians should con-
sider prophylactic anti-coagulation or routine Doppler 
ultrasound scan monitoring in HIV patients with low 
CD4 counts and PIs who are immobile knowing that they 
may develop an asymptomatic DVT. Patients using oral 
contraception on PIs and with low CD4 count should 
be counselled on signs and symptoms of DVT that they 
should report to their doctor and should be monitored 
closely for DVT.
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